RCS - Venture Life Group - Notice of analyst & investor results briefings

Venture LifeAnnouncement

05/03/2018 07:05

RNS Number : 6017G
Venture Life Group PLC
05 March 2018
5 March 2018
Venture Life Group plc
("Venture Life" or the "Group")
Notice of Results
Analyst & investor briefings
Venture Life Group plc (AIM: VLG), the international consumer healthcare group focused on developing, manufacturing and commercialising products for the self-care market, announces that it will releaseits final results for the year ended 31 December 2017 on 22 March 2018.
Analyst briefing
A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Thursday, 22 March 2018.
Investor briefing
A presentation to private investors will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, London EC2N 1DX on Monday, 26 March 2018 from 4.30pm for a 4.45pm start and will be followed by drinks.
If you would like to register to attend either briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or emailventurelife@walbrookpr.com.
For further information, please contact:
Venture Life Group PLC
+44 (0) 1344 742870
Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer



Walbrook PR
venturelife@walbrookpr.com or +44 (0) 20 7933 8780
Paul McManus
+44 (0) 7980 541 893
Anna Dunphy
+44 (0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising self-care products globally. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its Development & Manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFERVTIFIIT